Navigation Links
Using a child's own stem cells to repair their heart looks promising
Date:1/27/2011

Visionaries in the field of cardiac therapeutics have long looked to the future when a damaged heart could be rebuilt or repaired by using one's own heart cells. A study published in the February issue of Circulation, a scientific journal of the American Heart Association, shows that heart stem cells from children with congenital heart disease were able to rebuild the damaged heart in an animal model.

Sunjay Kaushal, MD, PhD, surgeon in the Division of Cardiovascular Thoracic Surgery at Children's Memorial Hospital and assistant professor of surgery at Northwestern University Feinberg School of Medicine, who headed the study, believes these results show great promise for the growing number of children with congenital heart problems. With this potential therapy option they could avoid the need for a heart transplant.

"Because of the advances in surgical and medical therapies, many children born with cardiomyopathy and other heart defects are living longer but may eventually succumb to heart failure," said Kaushal. "This project has generated important pre-clinical laboratory data showing that we may be able to use their own heart stem cells to rebuild their hearts, allowing these children to live longer and have more productive lives."

Cells were obtained from patients with ages ranging a few days after birth to 13 years who were undergoing routine congenital cardiac surgery. Findings show that the number of heart stem cells, or human cardiac progenitor cells (hCPCs), was greatest in neonates and then rapidly decreased with age, and that the highest numbers of these stem cells are located in the upper right chamber of the heart, or the right atrium. The study also showed that the hCPCs are functional and have the potential for use in repairing the damaged heart.

Up until now, heart stem cell studies have addressed the adult diseased heart, but this is the first systematic study to focus on children.

"H
'/>"/>

Contact: Julie Pesch
jpesch@childrensmemorial.org
773-880-3055
Children's Memorial Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. The world can be powered by alternative energy, using todays technology, in 20-40 years
2. Researchers register new species using DNA-based description
3. Forum to focus on using robotics, imaging and simulation in surgeries
4. EU grant for better monitoring of Crohns disease using MRI
5. Despite damage, membrane protein structure can be seen using new X-ray technology, study reveals
6. Cholera strain evolves new mechanism for causing disease
7. Using chaos to model geophysical phenomena
8. Using plants against soils contaminated with arsenic
9. Listeria clever at finding its way into bloodstream, causing sickness
10. Japanese researchers report on liver transplantation studies using animal and iPS cells
11. Team of chemists produces biodiesel at their university, using used cooking oil as a basis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... today at its 2005 international symposium on Computational ... Folding Project launched on IBM's World Community Grid ... structures. , "This project showcases the enormous power ... at the Institute for Systems Biology. "Through a ...
... body's infection-fighting cells might also contribute to fatty buildups ... Southwestern Medical Center researchers have found. , The molecule, ... death in macrophages, which circulate in the bloodstream and ... The AIM-protected macrophages go on to encourage buildup of ...
... life detection system developed by Carnegie Mellon University scientists ... according to results being presented at the 36th Lunar ... marks the first time a rover-based automated technology has ... which serves as a test bed for technology that ...
Cached Biology News:Institute for Systems Biology Symposium Addresses Need for Better Computational Tools 2Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries 2Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 2Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 3Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 4
(Date:1/22/2015)... 22, 2015 zFlo Motion , a ... announce an exciting product from a new partner. STT-Systems ... over the past 15 years, with offerings in the optical-motion ... 3D IMU system (inertial measurement unit), iSen, is opening eyes ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with ... used for drug discovery to commercial manufacturing, announced today ... Next-Generation Sequencing (NGS) data packages. The NGS analysis ... ensuring the integrity of the gene, validation of the ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... ATLANTA, April 4, 2011 CryoLife, Inc. (NYSE: ... processing company, announced today that it has filed ... (FDA) to begin clinical trials for the purpose of obtaining ... control bleeding during surgical procedures or following traumatic injuries. ...
... ORLEANS, April 4, 2011 Orexigen ® ... additional data that showed that overweight and obese ... SR) maintained normal 24-hour circadian patterns over one ... ambulatory blood pressure monitoring (ABPM) sub-study of the ...
... (NASDAQ: OMER ), a biopharmaceutical company committed ... bleeding and disorders of the central nervous system, today ... executive officer, is scheduled to present at the 10th ... City this week.  The presentation is scheduled for Tuesday, ...
Cached Biology Technology:CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 2Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 3Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 4
Anti-rat Dipeptidyl Peptidase IV (DPP IV), CD26, Clone 5E8, Monoclonal Antibody...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
... H3 (Lys 4) Immunogen: ... ...RT[ Ac K]Q... in which [ Ac ... human histone H3 Accession ... Weight: Mr ~17kDa ...
... The FastPlax Antibody is used to detect ... the surface of infected cells as early ... basis of the FastPlax Titer Kit, which ... 25-48 hours. The FastPlax Antibody ...
Biology Products: